# UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib

> **NCT02140840** · PHASE2 · WITHDRAWN · sponsor: **University of Arkansas**

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Trametinib

## Key facts

- **NCT ID:** NCT02140840
- **Lead sponsor:** University of Arkansas
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-03
- **Primary completion:** 2016-04
- **Final completion:** 2016-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** PI left institution
- **Last updated:** 2016-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02140840

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02140840, "UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02140840. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*